Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.
You may also be interested in...
In a partial buy-out by new private equity investor Madison Dearborn Partners, Ikaria is refocused on building out its critical care product portfolio, while a new R&D spin-out may take a route to the public markets. Existing investors have already done nicely through a series of dividends.
Ikaria shareholders sold the commercial side of that critical care business, but retained a stake in the off-loaded assets. While gastrointestinal and cystic fibrosis company Aptalis turns to an IPO instead of an acquisition.
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.